Isabelle M. Berquin
Wayne State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Isabelle M. Berquin.
Apmis | 1999
Barbara A. Frosch; Isabelle M. Berquin; Michael R. Emmert-Buck; Kamiar Moin; Bonnie F. Sloane
Upregulation, membrane association and secretion of cathepsin B have been shown to occur in many types of tumors and to correlate positively with their invasive and metastatic capabilities. To further understand changes in cathepsin B activity and localization, we have been examining its regulation at many levels including transcription and trafficking. Our studies indicate that there may be three promoter regions in the cathepsin B gene. Of these, continued examination of the promoter upstream of exon I has indicated possible control by several regulatory factors including E‐box and Sp‐1 binding elements. Upregulation of cathepsin B at this level may account for some of the secretion of cathepsin B found in tumors. We have also gathered evidence that endo‐and exocytosis of cathepsin B may be regulated by ras and ras‐related proteins in addition to previously described trafficking systems. There is also evidence that several populations of lysosomes may exist and that trafficking to different populations may determine whether cathepsin B is secreted from the tumor cell or remains intracellular. Our results indicate that membrane association and secretion of cathepsin B is not a random process in the tumor cell, but rather part of a tightly controlled system.
Oncogene | 2005
Isabelle M. Berquin; Bing Pang; Michele L. Dziubinski; Latanya M Scott; Yong Q. Chen; Garry P. Nolan; Stephen P. Ethier
The epidermal growth factor receptor (EGFR) is linked to poor outcome in breast cancer, and resistance to hormonal therapy is often accompanied by activation of growth factor receptors. To investigate the mechanism(s) by which EGFR becomes activated in breast cancer, we screened a cDNA expression library for genes that mediate EGF-independent proliferation of human mammary epithelial cells (HMECs). We isolated the NSEP1 cDNA encoding Y-box-binding protein 1 (YB-1), a multifunctional transcriptional and translational regulator. This cDNA conferred growth factor independence to HMECs. YB-1-transduced cells overexpressed EGFR, but ErbB-2 (Her-2/neu) levels were unchanged. Moreover, EGFR was constitutively phosphorylated in the absence of exogenous ligand. In these cells, an EGFR-blocking antibody failed to inhibit proliferation, conditioned medium activity could not be detected, and the synthesis of EGFR ligands was reduced compared to parental cells. This suggests that EGFR is activated in a ligand-independent fashion. However, cell growth could be blocked with an ErbB kinase inhibitor, indicating that EGFR signaling plays a major role in YB-1-induced growth factor independence. Taken together, our results demonstrate that YB-1 overexpression can induce EGF independence in HMECs via activation of the EGFR pathway. This could represent one of the mechanisms by which YB-1 contributes to breast tumor aggressiveness.
Perspectives in Drug Discovery and Design | 1995
Isabelle M. Berquin; Bonnie F. Sloane
The levels, subcellular distribution and ratio to endogenous inhibitors of cathepsins B and L are frequently altered in tumors. In several cases, these alterations correlate with tumor progression from benign to malignant, which suggests that cysteine proteases may contribute to tumor progression. Analysis and inhibition of cysteine proteases may therefore be clinically applicable in cancer. Several groups have found that cathepsin B serves as a diagnostic and prognostic marker of tumor progression, whereas in vitro and in vivo studies have shown that cysteine protease inhibitors can reduce tumor cell invasion and metastasis in some systems. Thus, cysteine proteases may prove to be an important target for therapeutic interventions aiming at reducing tumor metastasis.
Journal of Leukocyte Biology | 1999
Isabelle M. Berquin; Shiqing Yan; Kamna Katiyar; Li Huang; Bonnie F. Sloane; Bruce R. Troen
We utilized HL‐60 cells as a model system to examine the regulation of ctsb gene expression by differentiating agents. Inducers of monocytic differentiation [phorbol ester (PMA), calcitriol (D3), and sodium butyrate (NaB)] and inducers of granulocytic differentiation [all‐trans retinoic acid (RA) and 9‐cis retinoic acid (9‐cis RA)] increase ctsb mRNA levels in a dose‐dependent manner as determined by Northern blot hybridization. D3 and retinoids exert additive effects, suggesting that these agents act in part through distinct pathways. Actinomycin D decay experiments indicate that D3, NaB, RA, and 9‐cis RA do not alter mRNA stability. In contrast, PMA markedly increases the half‐life of ctsb mRNA. In transient transfection assays, PMA and NaB both stimulate transcription of the luciferase reporter gene placed under the control of ctsb promoter fragments. Thus, inducers of HL‐60 cell differentiation can regulate the expression of the ctsb gene at both transcriptional and posttranscriptional levels. J. Leukoc. Biol. 66: 609–616; 1999.
FEBS Letters | 1997
Isabelle M. Berquin; Mamoun Ahram; Bonnie F. Sloane
Transcripts for the cysteine protease cathepsin B are alternatively spliced in the untranslated regions (UTRs). We show that a cathepsin B probe containing 5′‐UTR sequences hybridized to an RNA of ∼300 nt in addition to the typical 2.2 and 4.0 kbp mRNAs. Within this 5′‐UTR, exon 2 was found to be homologous to Alu repetitive elements. Specifically, exon 2 was part of an Alu element interspersed with the cathepsin B gene. The ∼300 nt band that hybridized to our cathepsin B probe likely corresponds to Alu transcripts, which are known to accumulate in human cells. Indeed, a similarly migrating band was detected with an authentic Alu probe. Thus, we suggest that primary transcripts for cathepsin B contain Alu sequences which are preserved as exon 2 in some fully spliced mRNAs.
Advances in Experimental Medicine and Biology | 1996
Isabelle M. Berquin; Bonnie F. Sloane
DNA and Cell Biology | 2000
Shiqing Yan; Isabelle M. Berquin; Bruce R. Troen; Bonnie F. Sloane
Gene | 1995
Isabelle M. Berquin; Lequn Cao; Dunne Fong; Bonnie F. Sloane
Gene | 1994
Lequn Cao; R. Thomas Taggart; Isabelle M. Berquin; Kamiar Moin; Dunne Fong; Bonnie F. Sloane
Oncogene | 2001
Isabelle M. Berquin; Michele L. Dziubinski; Garry P. Nolan; Stephen P. Ethier